FIGHT: A phase 3 randomized, double-blind, placebo controlled study evaluating (bemarituzumab) FPA144 and modified FOLFOX6 (mFOLFOX6) in patients with previously untreated advanced gastric and gastroesophageal cancer with a dose finding phase 1 lead-in
| العنوان: | FIGHT: A phase 3 randomized, double-blind, placebo controlled study evaluating (bemarituzumab) FPA144 and modified FOLFOX6 (mFOLFOX6) in patients with previously untreated advanced gastric and gastroesophageal cancer with a dose finding phase 1 lead-in |
|---|---|
| المؤلفون: | Aaron Scott, Anteneh Tesfaye, Eric Cheung, Mohamedtaki Abdulaziz Tejani, Neyssa Marina, Janine Powers, Peter D. Eisenberg, Peter C. Enzinger, Daniel V.T. Catenacci, Charlie Zhang, Clarence Eng |
| المصدر: | Journal of Clinical Oncology. 36:TPS4135-TPS4135 |
| بيانات النشر: | American Society of Clinical Oncology (ASCO), 2018. |
| سنة النشر: | 2018 |
| مصطلحات موضوعية: | Cancer Research, medicine.medical_specialty, business.industry, Placebo-controlled study, Cancer, medicine.disease, Gastroenterology, FGFR2 Gene Amplification, Double blind, 03 medical and health sciences, Dose finding, 0302 clinical medicine, Gastroesophageal cancer, Oncology, 030220 oncology & carcinogenesis, Internal medicine, medicine, In patient, 030223 otorhinolaryngology, business, Lead (electronics) |
| الوصف: | TPS4135Background: FGFR2b overexpression and FGFR2 gene amplification occurs in approximately 10% of patients with gastric cancer (GC) and is associated with a poor prognosis and the presence of me... |
| تدمد: | 1527-7755 0732-183X |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_________::e4c2219fe7e0fec8a83cdfe5d8410b26Test https://doi.org/10.1200/jco.2018.36.15_suppl.tps4135Test |
| رقم الانضمام: | edsair.doi...........e4c2219fe7e0fec8a83cdfe5d8410b26 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 15277755 0732183X |
|---|